PremieHealth develops advanced nutritional supplements derived from human milk bioactives for preterm infants in Neonatal Intensive Care Units. Their engineered formulations optimize diet, development, and protection to improve long-term health outcomes for these vulnerable babies.
Funding
Funding not disclosed
Founders
Product
Problem
Current nutritional strategies for preterm infants, particularly those in Neonatal Intensive Care Units, are not optimized for their unique developmental stage. This suboptimal nutrition can lead to long-term health issues and increased healthcare costs.
Solution
PremieHealth is developing advanced nutritional supplements derived from human milk, specifically engineered to support the growth and development of preterm infants. Leveraging extensive research in milk and mammary gland biology, the company aims to provide a paradigm shift in neonatal nutrition. Their approach focuses on optimizing the diet, guiding development, and maximizing protection for these vulnerable infants. By translating scientific understanding of lactation into novel nutritional products, PremieHealth seeks to improve health outcomes and enable normal lifelong development for premature babies.
Target Audience
The primary customers are healthcare providers in Neonatal Intensive Care Units and the broader medical community focused on infant nutrition and development.
Features
- Nutritional supplements formulated from human milk bioactives.
- Targeted for preterm infants, with a focus on NICU populations.
- Based on extensive research in milk and mammary gland biology.
- Aims to optimize infant diet, development, and protection.
- Development of intellectual property and disruptive technologies in neonatal nutrition.